LEO Pharma’s sales engine is accelerating, but its next growth bet is already squeezing margins
LEO Pharma’s strategic brands are surging as dersimelagon expands its pipeline, but heavier investment is putting 2026 margins under pressure.
Pharma & Biotech
Pharma & Biotech
Why LEO Pharma is shifting the chronic hand eczema debate from skin clearance to life impact
New analyses from the DELTA FORCE and DELTA TEEN programmes extend the chronic hand eczema discussion beyond skin clearance. The findings could strengthen the clinical and economic case for delgocitinib, although real-world effectiveness, adolescent regulation and treatment access remain important tests.